Properties (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Medication
|
| gptkbp:approves |
gptkb:European_Union
gptkb:United_States |
| gptkbp:availableIn |
Prescription medication
|
| gptkbp:chemicalFormula |
C21H24N2O3
|
| gptkbp:clinicalTrials |
Phase III
|
| gptkbp:compatibleWith |
85%
|
| gptkbp:contraindication |
Pregnancy
Severe liver impairment |
| gptkbp:developedBy |
gptkb:HRA_Pharma
|
| gptkbp:dosageForm |
Tablet
|
| gptkbp:endOfLife |
Approximately 30 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ulipristal Acetate
|
| gptkbp:interactsWith |
CYP3A4 inhibitors
Hormonal contraceptives CYP3A4 inducers |
| gptkbp:isATypeOf |
126784-99-4
|
| gptkbp:issuedBy |
Oral tablet
|
| gptkbp:lastProduced |
2010
|
| gptkbp:marketedAs |
Ella
|
| gptkbp:numberOfStudents |
Urine
|
| gptkbp:operates_in |
G03AC05
|
| gptkbp:packaging |
Blister pack
|
| gptkbp:sideEffect |
Dizziness
Fatigue Nausea Headache Abdominal pain |
| gptkbp:storage |
Room temperature
|
| gptkbp:triggerType |
Selective progesterone receptor modulator
|
| gptkbp:usedFor |
Emergency contraception
|